ZA202304769B - Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer - Google Patents

Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer

Info

Publication number
ZA202304769B
ZA202304769B ZA2023/04769A ZA202304769A ZA202304769B ZA 202304769 B ZA202304769 B ZA 202304769B ZA 2023/04769 A ZA2023/04769 A ZA 2023/04769A ZA 202304769 A ZA202304769 A ZA 202304769A ZA 202304769 B ZA202304769 B ZA 202304769B
Authority
ZA
South Africa
Prior art keywords
pah
para
combination
aminohippuric acid
treating cancer
Prior art date
Application number
ZA2023/04769A
Other languages
English (en)
Inventor
Marian Meckel
Theresa Osl
Konstantin Zhernosekov
Original Assignee
Itm Isotope Tech Munich Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Itm Isotope Tech Munich Se filed Critical Itm Isotope Tech Munich Se
Publication of ZA202304769B publication Critical patent/ZA202304769B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2023/04769A 2020-11-05 2023-04-25 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer ZA202304769B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2020/081143 WO2022096103A1 (en) 2020-11-05 2020-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
PCT/EP2021/080822 WO2022096673A1 (en) 2020-11-05 2021-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer

Publications (1)

Publication Number Publication Date
ZA202304769B true ZA202304769B (en) 2024-10-30

Family

ID=73138835

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/04769A ZA202304769B (en) 2020-11-05 2023-04-25 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer

Country Status (13)

Country Link
US (1) US20230414796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7531707B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230127212A (cg-RX-API-DMAC7.html)
CN (1) CN116981487A (cg-RX-API-DMAC7.html)
AU (1) AU2021375728A1 (cg-RX-API-DMAC7.html)
DK (1) DK4065176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2967379T3 (cg-RX-API-DMAC7.html)
FI (1) FI4065176T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065304T2 (cg-RX-API-DMAC7.html)
PL (1) PL4065176T3 (cg-RX-API-DMAC7.html)
WO (2) WO2022096103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304769B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022007815A1 (tr) * 2022-05-13 2023-11-21 Ege Ueniversitesi Idari Ve Mali Islerdaire Bsk Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t
CN115212322B (zh) * 2022-06-01 2024-01-16 原子高科股份有限公司 一种用于放射性药物制备的冻干药盒及其制备方法
WO2025113628A1 (en) * 2023-11-30 2025-06-05 Full-Life Technologies Hk Limited Sstr receptor targeting radio compounds and uses thereof
EP4763231A1 (en) * 2024-12-20 2026-06-24 ITM Isotope Technologies Munich SE Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176427A (ja) 2004-12-21 2006-07-06 Geno Membrane:Kk エストロン3硫酸トランスポーター活性の阻害剤
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
CA2686933A1 (en) * 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) * 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance

Also Published As

Publication number Publication date
WO2022096103A1 (en) 2022-05-12
DK4065176T3 (da) 2024-01-02
FI4065176T3 (fi) 2024-01-18
PL4065176T3 (pl) 2024-03-18
AU2021375728A9 (en) 2024-06-20
CN116981487A (zh) 2023-10-31
JP7531707B2 (ja) 2024-08-09
US20230414796A1 (en) 2023-12-28
CA3171718A1 (en) 2022-05-12
ES2967379T3 (es) 2024-04-30
AU2021375728A1 (en) 2023-06-15
HUE065304T2 (hu) 2024-05-28
EP4065176A1 (en) 2022-10-05
KR20230127212A (ko) 2023-08-31
EP4065176B1 (en) 2023-10-11
JP2023547689A (ja) 2023-11-13
WO2022096673A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
GB0223380D0 (en) Combination therapy
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
ZA201907225B (en) Treatment of her2 positive cancers
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
IL191796A0 (en) Combination of zd6474 and pemetrexed
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2024000674A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
HUE065304T2 (hu) Para-aminohippursav (PAH) és radiojelölt komplexek kombinációja rák kezelésére
BRPI0517953A (pt) uso de zd 6474, ou de um sal farmaceuticamente aceitável do mesmo, e de um antiandrógeno, composição farmacêutica, kit, e, método para a produção de um efeito da redução da permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.
DK1653964T3 (da) Cancerkombinationsterapi omfattende AZD2171 og ZD1839
MX365308B (es) Fármaco de formulación de ion de sodio e ion de calcio para el tratamiento de cáncer, tumores y tumores no malignos.
NO20064755L (no) Kombinasjonsterapi
IL172682A0 (en) Combination therapy
IL177953A0 (en) Combination therapy including azd2171 and a taxane
MX2024001892A (es) Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos.
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126